专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008019199A8 FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译： FCγRIIB特异性抗体及其使用方法
公开(公告)号：WO2008019199A8
公开(公告)日：2015-10-29
申请号：PCT/US2007072153
申请日：2007-06-26
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING , GERENA ROBYN
发明人： JOHNSON LESLIE S , HUANG LING , GERENA ROBYN
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

2. 发明申请

WO2008019199A3 FC?RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译： FC？RIIB特异性抗体及其使用方法
公开(公告)号：WO2008019199A3
公开(公告)日：2008-07-31
申请号：PCT/US2007072153
申请日：2007-06-26
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING , GERENA ROBYN
发明人： JOHNSON LESLIE S , HUANG LING , GERENA ROBYN
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为单一药物治疗用于治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤的用途，特别是B细胞恶性肿瘤，B细胞慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

3. 发明申请

WO2008118324A2 COMPOSITION AND METHOD OF TREATING CANCER WITH AN ANTI-UROPLAKIN IB ANTIBODY 审中-公开
标题翻译：抗UROPLAKIN抗体治疗癌症的组合物和方法
公开(公告)号：WO2008118324A2
公开(公告)日：2008-10-02
申请号：PCT/US2008003635
申请日：2008-03-20
申请人： MACROGENICS INC , FERGUSON STACY , KOENIG SCOTT , TUAILLON NADINE , JOHNSON LESLIE S , HUANG LING , RANKIN CHRISTOPHER
发明人： FERGUSON STACY , KOENIG SCOTT , TUAILLON NADINE , JOHNSON LESLIE S , HUANG LING , RANKIN CHRISTOPHER
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/72 , C07K2317/732 , C07K2319/30
摘要： This invention provides antibodies that specifically recognize and bind to UPK-Ib. Also included are diagnostic and therapeutic assays directed to diseases associated with unregulated levels of UPK-Ib using said antibodies. The antibodies and derivatives thereof can also be useful in the diagnisic and/or treatment of cancer associated with abnormal expression of UPK-Ib.
摘要翻译：本发明提供了特异性识别和结合UPK-1b的抗体。还包括使用所述抗体针对与未调节水平的UPK-Ib相关的疾病的诊断和治疗测定。该抗体及其衍生物也可用于诊断和/或治疗与UPK-1b异常表达相关的癌症。

4. 发明申请

WO2009151717A3 BCR-COMPLEX-SPECIFIC ANTIBODIES AND METHODS OF USING SAME 审中-公开
标题翻译： BCR复合特异性抗体及其使用方法
公开(公告)号：WO2009151717A3
公开(公告)日：2010-05-20
申请号：PCT/US2009038171
申请日：2009-03-25
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING
发明人： JOHNSON LESLIE S , HUANG LING
IPC分类号： C07K16/00 , C12P21/08
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及特异性结合BCR复合物的嵌合和人源化抗体，特别是涉及BCR复合物的嵌合和人源化抗体。本发明还涉及将抗体及其组合物用于诊断，预后和治疗诸如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的疾病的方法。

5. 发明申请

WO2009117030A3 IMPROVED COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SMALLPOX 审中-公开
标题翻译：改进的预防和治疗小型组合物
公开(公告)号：WO2009117030A3
公开(公告)日：2010-01-14
申请号：PCT/US2008087390
申请日：2008-12-18
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING
发明人： JOHNSON LESLIE S , HUANG LING
IPC分类号： A61K39/00
CPC分类号： C07K16/081 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/55 , C07K2317/76
摘要： The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.
摘要翻译：本发明涉及用于预防和治疗天花的改进的组合物，特别是涉及使用含有抗体的组合物，所述组合物含有与在天花病毒MV形式上发现的表位结合的抗体，以及结合表位上发现的表位的抗体 EV形式的天花病毒。本发明涉及这样的组合物，特别是涉及非血液衍生的抗体组合物，例如嵌合或人源化抗体，以及它们用于在天花病毒感染风险或出现天花的个体赋予对天花感染的被动免疫的方法。

6. 发明申请

WO2008105886A3 HUMANIZED FC?RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：人类FC？RIIB特异性抗体及其使用方法
公开(公告)号：WO2008105886A3
公开(公告)日：2009-03-05
申请号：PCT/US2007069767
申请日：2007-05-25
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING
发明人： JOHNSON LESLIE S , HUANG LING
IPC分类号： A61K39/00 , C07K16/00
CPC分类号： A61K39/39 , A61K2039/505 , A61K2039/55516 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/52 , G01N33/564 , G01N33/6893 , G01N2800/24
摘要： The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.
摘要翻译：本发明涉及以比所述抗体更大的亲和力结合FcγRIIA的结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。本发明包括治疗自身免疫疾病的方法和消除表达FcγRIIB的癌细胞的方法。

7. 发明申请

WO2012162067A2 CD3-BINDING MOLECULES CAPABLE OF BINDING TO HUMAN AND NON-HUMAN CD3 审中-公开
标题翻译：可结合人和非人CD3的CD3结合分子
公开(公告)号：WO2012162067A2
公开(公告)日：2012-11-29
申请号：PCT/US2012038219
申请日：2012-05-16
申请人： MACROGENICS INC , HUANG LING , JOHNSON LESLIE S
发明人： HUANG LING , JOHNSON LESLIE S
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , C07K16/2803 , C07K16/2827 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to CD3 -binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.
摘要翻译：本发明涉及能够结合人和非人CD3，特别是与非人哺乳动物（例如食蟹猴）的CD3交叉反应的分子的CD3结合分子。本发明还涉及这种抗体和抗原结合片段在治疗癌症，自身免疫和/或炎性疾病和其他病症中的用途。

8. 发明申请

WO2008157379A2 COVALENT DIABODIES AND USES THEREOF 审中-公开
标题翻译：同性双胞胎及其用途
公开(公告)号：WO2008157379A2
公开(公告)日：2008-12-24
申请号：PCT/US2008066957
申请日：2008-06-13
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING
发明人： JOHNSON LESLIE S , HUANG LING
IPC分类号： C07K16/46
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/2803 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/62 , C07K2317/626 , C07K2317/64 , C07K2317/92
摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non- peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody- like functionality to engineered into the molecule.
摘要翻译：本发明涉及双抗体分子及其在治疗各种疾病和病症（包括免疫学疾病，感染性疾病，中毒和癌症）中的用途。本发明的双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链，其可识别相同或不同抗原上相同或不同的表位。另外，抗原可以来自相同或不同的分子。双抗体分子的单个多肽链可以通过非肽键共价键共价结合，例如但不限于位于每个多肽链内的半胱氨酸残基的二硫键。在具体实施方案中，本发明的双抗体分子还包含Fc区，其允许类似抗体的功能改造成分子。

9. 发明申请

WO2005110474A3 HUMANIZED Fc?RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：人类FcγRIIB特异性抗体及其使用方法
公开(公告)号：WO2005110474A3
公开(公告)日：2007-01-04
申请号：PCT/US2005016260
申请日：2005-05-10
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING
发明人： JOHNSON LESLIE S , HUANG LING
IPC分类号： C07K16/00 , A61K39/395 , A61K39/42 , C07H21/04 , C07K16/28 , C12N15/00 , C12N15/63
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34
摘要： The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.
摘要翻译：本发明涉及以比所述抗体更大的亲和力结合FcγRIIA的结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。本发明包括治疗自身免疫疾病的方法和消除表达FcγRIIB的癌细胞的方法。

10. 发明申请

WO2012162068A3 DEIMMUNIZED SERUM-BINDING DOMAINS AND THEIR USE FOR EXTENDING SERUM HALF-LIFE 审中-公开
标题翻译：消除血清结合域及其用于延长血清半衰期
公开(公告)号：WO2012162068A3
公开(公告)日：2014-02-20
申请号：PCT/US2012038227
申请日：2012-05-16
申请人： MACROGENICS INC , BONVINI EZIO , BARAT BHASWATI , HUANG LING , JOHNSON LESLIE S
发明人： BONVINI EZIO , BARAT BHASWATI , HUANG LING , JOHNSON LESLIE S
IPC分类号： C07K16/00 , A61K39/00 , C07K1/00
CPC分类号： C07K16/32 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/62 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2319/31 , C07K2319/32 , C07K2319/73
摘要： The disclosure is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunize serum-binding protein. Further disclosed are methods and uses that employ such molecules.
摘要翻译：本公开涉及包含能够结合所述血清蛋白的解除免疫的血清结合蛋白的多肽部分的多肽（例如，抗原结合分子）。如果缺乏去免疫的血清结合蛋白的多肽部分，则血清结合蛋白的存在相对于多肽的血清半衰期延长了多肽的血清半衰期。进一步公开的是使用这种分子的方法和用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式